Overview

• Pediatric orthopedics firm's preliminary Q4 revenue beat analyst expectations

• Company reported record preliminary full year 2025 revenue growth of 15% yr/yr

• Company projects 2026 revenue growth of 11% to 13% and $25 mln adjusted EBITDA

Outlook

• OrthoPediatrics projects 2026 revenue between $262 mln and $266 mln

• Company expects 2026 adjusted EBITDA of approximately $25 mln

• OrthoPediatrics sees specialty bracing as a strategic growth driver

Result Drivers

• TRAUMA AND DEFORMITY - Trauma and Deformity and Scoliosis implant businesses drove revenue growth and profitability, per CEO David Bailey

• SPECIALTY BRACING - OPSB business seen as a strategic catalyst and capital-efficient driver of revenue and earnings

• EUMDR CERTIFICATION - Achieved EUMDR certification for various products, potentially supporting future growth

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for OrthoPediatrics Corp is $23.50, about 28.3% above its January 9 closing price of $18.31

Press Release: ID:nGNX1BkhK5

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)